| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
EBI2 ( IC50 = 11 nM ); EBI2 ( IC50 = 16 nM )
NIBR-189 targets EBI2 (also known as GPR183), an oxysterol-activated G protein-coupled receptor. EBI2 is involved in immune cell migration, particularly B cell positioning in lymphoid tissues. It is activated by oxysterols (e.g., 7α,25-dihydroxycholesterol). By antagonizing EBI2, NIBR-189 inhibits oxysterol-mediated chemotaxis of immune cells. This mechanism underlies its potential in autoimmune disease research. The compound shows high potency against both human and mouse receptors. |
|---|---|
| ln Vitro |
NIBR189, an EBI2 antagonist, inhibits migration with an IC50 of 0.3 nM in U937 cells expressing functional EBI2 levels.[1]
In vitro, NIBR-189 potently inhibits human and mouse EBI2 with IC₅₀ values of 11 nM and 16 nM, respectively. It acts as a competitive antagonist, blocking oxysterol binding to EBI2. The compound demonstrates selectivity for EBI2 over other GPCRs. In cell-based assays, NIBR-189 inhibits EBI2-mediated chemotaxis and signaling. Detailed binding and functional data are available in the primary literature. |
| ln Vivo |
NIBR189 possesses pharmacokinetic qualities that should enable its application in both in vitro and in vivo research. It is a strong and selective EBI2 antagonist.[1]
In vivo data for NIBR-189 are limited in publicly available sources. Based on its potency and selectivity, the compound is expected to be useful for in vivo studies of EBI2 function in immune cell trafficking and autoimmune disease models. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a research tool for immunology studies. |
| Enzyme Assay |
In vitro receptor binding assays for NIBR-189 typically use membrane preparations from cells expressing human or mouse EBI2 receptors. Radioligand binding is performed using [³H]7α,25-dihydroxycholesterol or other EBI2 radioligands. Membranes are incubated with radioligand and varying concentrations of NIBR-189 in assay buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl₂, 0.1% BSA) at room temperature for 1-2 hours. Nonspecific binding is determined using excess unlabeled ligand. Bound radioactivity is measured by scintillation counting. Ki and IC₅₀ values are calculated by nonlinear regression. Functional assays may include GTPγ³⁵S binding.
|
| Cell Assay |
U937 cells were cultured in lipid-depleted media for the entire night before the migration assay. Using HTS Transwell-96 plates with 5.0 μm pore polycarbonate membranes, chemotaxis was carried out. Let's recap: 240 μL of compound solution in media containing 1% BSA instead of FCS was placed in lower chambers, and 0.75×105 cells in 75 μL media were added to the upper chamber once the filters were inserted. Using flow cytometry, the cells in the lower chamber were examined after three hours at 37°C.
For cell-based assays, cells expressing recombinant human or mouse EBI2 (e.g., CHO or HEK-293 cells) are cultured in DMEM with 10% FBS and selection antibiotics. Cells are seeded in 96-well plates and treated with NIBR-189 at various concentrations (0.1 nM-10 μM) for 30-60 minutes. Chemotaxis assays are performed using transwell plates with oxysterol as chemoattractant. Calcium mobilization assays may also be used. IC₅₀ values are calculated from dose-response curves. All treatments include vehicle controls and are performed in triplicate. |
| Animal Protocol |
C57BL/6 male mice
1 mg/kg (i.v.); 3 mg/kg (p.o.) i.v., p.o. In vivo, NIBR-189 may be administered to rodents via IP or oral routes. For autoimmune disease models (e.g., experimental autoimmune encephalomyelitis or collagen-induced arthritis), compound is dosed at various regimens. Endpoints include clinical scoring, immune cell infiltration, and histopathology. Blood and tissues are collected for pharmacokinetic analysis and biomarker assessment. All procedures follow institutional animal care guidelines. |
| ADME/Pharmacokinetics |
NIBR-189 is a potent and selective EBI2 antagonist with IC₅₀ values of 11 nM (human) and 15-16 nM (mouse). Detailed pharmacokinetic parameters (bioavailability, half-life, clearance) are not extensively reported in publicly available sources. The compound is designed for research applications in immunology. Further ADME studies are needed to fully characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
Toxicology data for NIBR-189 are limited in publicly available sources. As a GPCR antagonist, potential off-target effects on other receptors should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
NIBR-189 is a research-grade EBI2 (GPR183) antagonist for studying immune cell migration and autoimmune diseases. Its primary applications include immunology and inflammation research. The compound is not approved for clinical use and has not entered clinical trials. It is a valuable tool for elucidating the role of EBI2 in immune responses. The compound is commercially available from various chemical suppliers for research purposes only.
|
| Molecular Formula |
C21H21BRN2O3
|
|---|---|
| Molecular Weight |
429.314
|
| Exact Mass |
428.074
|
| Elemental Analysis |
C, 58.75; H, 4.93; Br, 18.61; N, 6.53; O, 11.18
|
| CAS # |
1599432-08-2
|
| PubChem CID |
36295259
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.331
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C(=C([H])C=1[H])/C(/[H])=C(\[H])/C(N1C([H])([H])C([H])([H])N(C(C2C([H])=C([H])C(=C([H])C=2[H])OC([H])([H])[H])=O)C([H])([H])C1([H])[H])=O
|
| InChi Key |
OFHXXBRBGWUOHR-NYYWCZLTSA-N
|
| InChi Code |
InChI=1S/C21H21BrN2O3/c1-27-19-9-5-17(6-10-19)21(26)24-14-12-23(13-15-24)20(25)11-4-16-2-7-18(22)8-3-16/h2-11H,12-15H2,1H3/b11-4+
|
| Chemical Name |
(E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one
|
| Synonyms |
NIBR189; NIBR 189; NIBR-189
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~21~50 mg/mL (~48.9~116.5 mM)
Ethanol: ~4 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.82 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: (saturation unknown) in 5%DMSO + 40%PEG300 + 5%Tween 80+ 50%ddH2O：1.05mg/ml (2.45mM) (add these co-solvents sequentially from left to right, and one by one), |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3293 mL | 11.6466 mL | 23.2932 mL | |
| 5 mM | 0.4659 mL | 2.3293 mL | 4.6586 mL | |
| 10 mM | 0.2329 mL | 1.1647 mL | 2.3293 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
